New England Journal of Medicine Publishes New Analyses Confirming that Sanofi Pasteur's Vaccine Candidate Safely Protects Pre-Adolescents to Adults Against Dengue - Seite 3

Dengue is the world's fastest growing vector-borne disease, endemic in over 100 countries where almost half the world's population resides. Dengue poses considerable economic and human burden in these endemic countries as it is prone to unpredictable outbreaks and spreads readily in densely populated urban areas, often paralyzing local healthcare systems and requiring cost-intensive intervention efforts. Today, no specific treatment or prevention for dengue is available.

The WHO has set objectives to reduce mortality due to dengue by 50% and morbidity by 25% by 2020. Introduction of an effective and safe dengue vaccine as an integral part of dengue prevention efforts will be critical to achieving this goal.

Based on the totality of the safety and efficacy data for its dengue vaccine candidate, Sanofi Pasteur has decided to recommend a targeted age indication for the vaccine of 9 years of age and older in endemic countries, where the combination of disease burden and the vaccine's proven impact profile in this age group point to the greatest potential for reduction of dengue disease burden in these countries.

[1] L'Azou M, Moureau A, Sarti E, et al. Incidence of symptomatic pediatric dengue in ten Asian and Latin American countries. . N Engl J Med 2015; Manuscript resubmitted.
[2] L'Azou M, Taurel AF, Flamand C, Quenel P. Recent epidemiological trends of dengue in the French territories of the Americas (2000-2012): a systematic literature review. PLoS Negl Trop Dis 2014;8:e3235.
[3] San Martin JL, Brathwaite O, Zambrano B, et al. The epidemiology of dengue in the americas over the last three decades: a worrisome reality. Am J Trop Med Hyg 2010;82:128-35.
[4 ]Capeding M.R. et.al, Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial ; Volume 384, Issue 9951, 11-17 October 2014, Pages 1358-1365
[5] Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015

About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).